SWOG S1613

Primary Category:

Treatment Protocols

Disease Category:

Colon, Colon Metastatic, Gastrointestinal, Rectal, Rectal Metastatic

Status:

Closed

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

S1613, Step 2 (randomization) is permanently closed to accrual, effective March 31, 2022.

S1613 is permanently closed to accrual, effective December 31, 2021.

NCT#03365882